A team of researchers from the Wyss Institute has found a way to embed synthetic biology reactions into fabrics, creating wearable biosensors that can be customized to detect pathogens and toxins and alert the wearer.

A Wyss Institute-led collaboration has used the institute’s organ-on-a-chip technology to identify the antimalarial drug amodiaquine as a potent inhibitor of infection with SARS-CoV-2, the virus that causes COVID-19.

A concept for seeded all-or-nothing assembly of micron-scale DNA nanostructures that could extend nanofabrication capabilities and enable creation of highly specific diagnostics.

Delivering immune-stimulating nanoparticles to the lungs via red blood cells halts tumor growth in mice.

Controlling a DNA-synthesizing enzyme with photolithographic methods from the computer chip industry facilitates multiplexed writing and storage of digital data in DNA.

Computational algorithms enable identification and optimization of RNA-based tools for myriad applications.

A biomaterials-based infection vaccine strategy shows first promise in eliciting immunity against SARS-CoV-2 and could be applied broadly to stave off infectious disease.

The Wyss Institute made improvements to its face shields based on recommendations from area hospitals. Joining forces with a Mansfield, Mass.-based manufacturer, the institute’s face shields are now being produced at a rate of 400,000 a day.

New platform technology uses red blood cells to generate targeted immune responses in mice